Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia.

Denis Y LogunovAlexander L Gintsburg


We developed a heterologous COVID-19 vaccine consisting of two components, a recombinant adenovirus type 26 (rAd26) vector and a recombinant adenovirus type 5 (rAd5) vector, both carrying the gene for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein (rAd26-S and rAd5-S). We aimed to assess the safety and immunogenicity of two formulations (frozen and lyophilised) of this vaccine. We did two open, non-randomised phase 1/2 studies at two hospitals in Russia. We enrolled healthy adult volunteers (men and women) aged 18-60 years to both studies. In phase 1 of each study, we administered intramuscularly on day 0 either one dose of rAd26-S or one dose of rAd5-S and assessed the safety of the two components for 28 days. In phase 2 of the study, which began no earlier than 5 days after phase 1 vaccination, we administered intramuscularly a prime-boost vaccination, with rAd26-S given on day 0 and rAd5-S on day 21. Primary outcome measures were antigen-specific humoral immunity (SARS-CoV-2-specific antibodies measured by ELISA on days 0, 14, 21, 28, and 42) and safety (number of participants with adverse events monitored throughout the study). Secondary outcome measures were antigen-specific cellular immuni...Continue Reading


Feb 24, 2004·The Journal of Gene Medicine·Christoph Volpers, Stefan Kochanek
Sep 29, 2004·Molecular Therapy : the Journal of the American Society of Gene Therapy·Nia Tatsis, Hildegund C J Ertl
Jun 9, 2009·Current Opinion in Immunology·Shan Lu
Nov 12, 2009·Blood·Jeffrey D Ahlers, Igor M Belyakov
Feb 9, 2011·Nature Biotechnology·Cormac Sheridan
Nov 28, 2013·Current Gene Therapy·William S M Wold, Karoly Toth
Apr 23, 2016·Human Vaccines & Immunotherapeutics·Chao Zhang, Dongming Zhou
May 11, 2016·Molecular Therapy. Methods & Clinical Development·Sam AfkhamiZhou Xing
Jan 18, 2018·Human Gene Therapy·Wei-Wei ZhangDominic Man-Kit Lam
Oct 5, 2018·Frontiers in Immunology·Susanne RauchBenjamin Petsch
May 16, 2019·Journal of Immunology Research·Ayman MubarakMaged Gomaa Hemida
Feb 23, 2020·Biochemical and Biophysical Research Communications·Yun ChenZhizhuang Joe Zhao
Apr 7, 2020·Trends in Immunology·Shibo JiangLanying Du
May 16, 2020·Biochemical and Biophysical Research Communications·Houcemeddine OthmanScott Hazelhurst
Jul 15, 2020·The New England Journal of Medicine·Lisa A JacksonUNKNOWN mRNA-1273 Study Group

❮ Previous
Next ❯


Sep 24, 2020·Nature·Florian Krammer
Sep 20, 2020·International Journal of Molecular Sciences·Arun Samidurai, Anindita Das
Sep 30, 2020·Nature Biotechnology·Laura DeFrancesco
Sep 12, 2020·BMJ : British Medical Journal
Oct 7, 2020·Environment, Development and Sustainability·Harekrishna Bar
Oct 18, 2020·Nature Reviews. Microbiology·Shan SuShibo Jiang
Sep 17, 2020·Clinical and Experimental Immunology·John S TregoningKatrina M Pollock
Oct 15, 2020·Signal Transduction and Targeted Therapy·Yetian DongFangfang Zhou
Nov 6, 2020·Médecine sciences : M/S·Emmanuelle Billon-Denis, Jean-Nicolas Tournier
Dec 3, 2020·Respiratory Research·Meghana RastogiSunit K Singh
Dec 4, 2020·Human Vaccines & Immunotherapeutics·Vipin M Vashishtha, Puneet Kumar
Dec 16, 2020·SLAS Discovery·Dawid MaciorowskiAdinarayana Kunamneni
Dec 22, 2020·Expert Opinion on Pharmacotherapy·Iwona HusTadeusz Robak
Dec 31, 2020·Vaccines·Shilu MathewHadi M Yassine
Jan 2, 2021·Proceedings of the National Academy of Sciences of the United States of America·B David PerssonNiklas Arnberg
Jan 5, 2021·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Nikoo Hossein-KhannazerMassoud Vosough
Dec 9, 2020·British Journal of Clinical Pharmacology·Ester Calvo Fernández, Lucie Y Zhu
Sep 9, 2020·Lancet·Naor Bar-Zeev, Tom Inglesby
Jan 12, 2021·Advanced Drug Delivery Reviews·Jatin MachhiBhavesh D Kevadiya
Jan 5, 2021·Transplant Infectious Disease : an Official Journal of the Transplantation Society·Tommaso M ManziaGiuseppe Tisone
Nov 21, 2020·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Vladislav IzdaAmr H Sawalha
Jan 27, 2021·Cells·Rameswari Chilamakuri, Saurabh Agarwal
Nov 24, 2020·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Bianza Moise BakadiaGuang Yang
Nov 13, 2020·Frontiers in Pharmacology·Junqing HuangJia-Xu Chen
Dec 19, 2020·Nature Medicine·Jordan R BarrettUNKNOWN Oxford COVID Vaccine Trial Group
Dec 21, 2020·Journal of Biomedical Science·Yen-Der LiT-C Wu
Dec 31, 2020·Microorganisms·Luis Jiménez-CabelloAlejandro Marín-López
Jan 11, 2021·Advanced Drug Delivery Reviews·Deborah PushparajahRoderick A Slavcev
Jan 17, 2021·Vaccines·Wojciech FeleszkoPaweł Waszkiewicz
Dec 3, 2020·Canadian Journal of Microbiology·Raquel L RussellBrian L Mark
Dec 20, 2020·Nature Reviews. Immunology·Lianpan Dai, George F Gao
Dec 24, 2020·Der Internist·M AugustinS Nitschmann
Dec 30, 2020·Vaccines·Nicholas W Lukacs, Carrie-Anne Malinczak
Jan 7, 2021·Military Medical Research·Dan-Dan Li, Qi-Han Li
Jan 12, 2021·Frontiers in Immunology·Jing ZhaoQiwei Zhang
Feb 5, 2021·Science Translational Medicine·Wayne C KoffJaap Goudsmit

❮ Previous
Next ❯

Methods Mentioned

flow cytometry
plasma collection

Clinical Trials Mentioned


Related Concepts

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.


Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.


Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.